ArticleCurrent microbiology2025
Weissella confusa MW051433 Mitigates Hypercholesterolemia by Biliary Cholesterol Excretion: The In Vivo Evidence.
Article in Current microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
The current study explored cholesterol-lowering potential and the underlying mechanism (biliary cholesterol excretion) of a prebiotic (mannitol), probiotic (Weissella confusa MW051433), and their synbiotic (mannitol + W. confusa MW051433) in high fat diet induced hypercholesterolemic murine model. The experiment employed a randomized controlled design consisting of five groups: negative control, positive control and three treatment groups, with six rats in each group. Positive control and treatment groups were maintained on high fat (18.37%) diet throughout experimental period (60 days). The high-fat diet induced significant (p < 0.05) augmentation in total serum cholesterol, triglycerides, low-density lipoprotein and decrease in high-density lipoprotein within 15 days. By 60th day of experiment, it further led to elevation in liver cholesterol, and hepatic enzymes, and depletion in hemoglobin (35.85%), erythrocytes (34.78%), and hematocrit (27.31%) in PC group. ANOVA followed by Tukey's test revealed that treatment (day 15-60 of experiment) with W. confusa MW051433 and its synbiotic, significantly improved blood lipid profile, liver functions and led to remarkable increase in fecal cholesterol (70.48%, 107.85%) and cholic acid (123.21%, 100.91%) content, respectively. Histopathological findings, including hepatic lipid droplet count, adipocyte size, and cellular integrity, further indicated that the strain facilitated cholesterol reduction through biliary cholesterol excretion mechanism. While the synbiotic showed slight superiority in one parameter, the probiotic alone yielded comparable results. To our information, this is the first report on in vivo hypocholesterolemic efficacy of W. confusa MW051433. Further research exploring its role in cholesterol homeostasis through in silico modeling, and gene/protein expression, is recommended.
Indexed as
Identifiers
40169457What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.